PMV PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • September 4th, 2020 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of , and is between PMV Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • October 5th, 2021 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
PMV Pharmaceuticals, Inc. [●] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • September 21st, 2020 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
PMV Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares of common stock, par value $0.00001 per share (the “Common Stock”), of the Company (the “Firm Shares”) and, at the election of the Underwriters, up to [●] additional shares (the “Optional Shares”) of Common Stock (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
LEASE by and between BMR-ONE RESEARCH WAY LLC, a Delaware limited liability company and PMV PHARMACEUTICALS, INC., a Delaware corporationLease • March 3rd, 2021 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS LEASE (this “Lease”) is entered into as of this 8th day of January, 2021 (the “Execution Date”), by and between BMR-ONE RESEARCH WAY LLC, a Delaware limited liability company (“Landlord”), and PMV PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
August 11, 2020 Winston Kung c/o PMV Pharmaceuticals, Inc. Dear Winston,Employment Agreement • September 4th, 2020 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations
This letter agreement (the “Agreement”) is entered into between you and PMV Pharmaceuticals, Inc. (the “Company,” “PMV Pharma,” or “we”). This Agreement is effective as of the date hereof (the “Effective Date”). The purpose of this Agreement is to confirm the current terms and conditions of your employment.
PMV PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT July 17, 2020Investors’ Rights Agreement • September 4th, 2020 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is dated as of July 17, 2020 and is by and among PMV Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the persons and entities listed on Exhibit A (each, an “Investor” and collectively, the “Investors”) and the entities listed on Exhibit B (each, a “Licensor,” and collectively, the “Licensors”).
Change in Control and Severance Policy Amended and Restated Participation AgreementParticipation Agreement • September 4th, 2020 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Participation Agreement (“Agreement”) is made and entered into by and between Winston Kung on the one hand, and PMV Pharmaceuticals, Inc. (the “Company”) on the other.
PMV PHARMA CONSULTING AGREEMENTConsulting Agreement • September 4th, 2020 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into by and between PMV PHARMA, a Delaware corporation (the “Company”), and Arnold Levine, Ph.D., an individual (“Consultant”), effective as of January 1, 2016 (“Effective Date”).
LEASE AGREEMENTLease Agreement • September 4th, 2020 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
AGREEMENT, made February , 2015, between Cedar Brook 2005, LP, 4A Cedar Brook Drive, Cranbury, New Jersey 08512, “Landlord”; and PMV Pharmaceuticals, Inc., 497 Seaport Court, Suite 101, Redwood City, CA 94063, “Tenant”.
Change in Control and Severance Policy (the "Policy") Amended and Restated Participation AgreementParticipation Agreement • February 29th, 2024 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Participation Agreement ("Agreement") is made and entered into by and between Michael Carulli, on the one hand, and PMV Pharmaceuticals, Inc. (the "Company") on the other.
Change in Control and Severance Policy Amended and Restated Participation AgreementChange in Control and Severance Policy Participation Agreement • March 1st, 2022 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Participation Agreement ("Agreement") is made and entered into by and between Deepika Jalota on the one hand, and PMV Pharmaceuticals, Inc. (the "Company") on the other.
Change in Control and Severance Policy Amended and Restated Participation AgreementParticipation Agreement • September 4th, 2020 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Participation Agreement (“Agreement”) is made and entered into by and between Deepika Jalota on the one hand, and PMV Pharmaceuticals, Inc. (the “Company”) on the other.
PMV PHARMACEUTICALS, INC. CONSULTING AGREEMENTConsulting Agreement • February 29th, 2024 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
THIS CONSULTING AGREEMENT (the "Agreement") is made and entered into by and between PMV PHARMACEUTICALS, INC., a Delaware corporation (the "Company"), and Charles Baum, M.D., Ph.D., an individual ("Consultant"), effective as of the date of last signature hereto ("Effective Date").
February 22, 2021 Deepika Jalota, Pharm.D. c/o PMV Pharmaceuticals, Inc. Dear Deepika,Employment Agreement • March 1st, 2022 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations
This letter agreement (the “Agreement”) is entered into between you and PMV Pharmaceuticals, Inc. (the “Company,” “PMV Pharma,” or “we”), and amends and restates in full your earlier Employment Letter dated August 11, 2020, reflecting your promotion and related compensation changes. This Agreement is effective as of the date hereof (the “Effective Date”).
LEASE TERMINATION AGREEMENTLease Termination Agreement • August 8th, 2024 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS LEASE TERMINATION AGREEMENT (this “Agreement”) is entered into as of this 5th day of August, 2024 (“Execution Date”), by and between BMR-ONE RESEARCH WAY LLC, a Delaware limited liability company (“Landlord”), and PMV PHARMACEUTICALS, Inc., a Delaware corporation (“Tenant”).
Amended and Restated Participation AgreementParticipation Agreement • May 10th, 2022 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Participation Agreement (“Agreement”) is made and entered into by and between Deepika Jalota on the one hand, and PMV Pharmaceuticals, Inc. (the “Company”) on the other.
PMV PHARMACEUTICALS, INC. CONSULTING AGREEMENTConsulting Agreement • February 29th, 2024 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into by and between PMV PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and Winston Kung, an individual (“Consultant”), effective as of January 05, 2024 (“Effective Date”).
January 05, 2024 Michael Carulli c/o PMV Pharmaceuticals, Inc. Dear Mike,Employment Agreement • February 29th, 2024 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations
This letter agreement (the "Agreement" ) is entered into between you and PMV Pharmaceuticals, Inc. (the "Company," "PMV Pharma," or "we"), and amends and restates in full your earlier Employment Letter dated March 30, 2020, reflecting your promotion and related compensation changes. This Agreement is effective as of the date hereof (the "Effective Date") .
AMENDED & RESTATED SAB CONSULTING AGREEMENTSab Consulting Agreement • March 1st, 2022 • PMV Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into by and between PMV PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and Richard Heyman, Ph.D., an individual (“Consultant”), effective as of May 15, 2021 (“Effective Date”).
